Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALTAFLUOR BENOX vs CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ALTAFLUOR BENOX is a combination of benoxinate, a local anesthetic that reversibly blocks sodium ion channels in nerve cell membranes, stabilizing the neuronal membrane and inhibiting the initiation and conduction of nerve impulses, and fluorescein, a fluorescent dye that stains epithelial defects in the cornea. Local anesthetic effect occurs within seconds.
Sodium picosulfate is a stimulant laxative that is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane, which stimulates colonic peristalsis by acting on the colonic mucosa and inhibiting water and electrolyte absorption. Magnesium oxide acts as an osmotic laxative by drawing water into the intestinal lumen. Citric acid reacts with magnesium oxide to form magnesium citrate, an osmotic laxative.
FDA: For topical ophthalmic anesthesia and as a disclosing agent during ophthalmic procedures (e.g., tonometry, gonioscopy, removal of foreign bodies, sutures).,Off-label: No well-established off-label uses.
Bowel cleansing prior to colonoscopy,FDA-approved for bowel preparation in adults
1-2 drops of 0.4% benoxinate hydrochloride ophthalmic solution instilled into the conjunctival sac prior to diagnostic procedures or surgery.
Adult: 10 mg oral sodium picosulfate (as 10 mg powder for oral solution) plus 3.5 g magnesium oxide and 12 g citric acid, taken as a single dose the day before colonoscopy, followed by a second dose the next morning, for a total of 2 doses.
Terminal elimination half-life: 1.0–1.5 hours in adults with normal renal function; prolonged to 6–10 hours in severe renal impairment (Cr Cl <30 m L/min).
The terminal elimination half-life of the active metabolite BHPM is approximately 7-9 hours; clinical effect (bowel cleansing) begins within 1-3 hours and is complete by 6 hours.
Systemic absorption is minimal after ophthalmic administration. Benoxinate is hydrolyzed by plasma esterases; metabolites are excreted renally. Fluorescein is metabolized via glucuronidation in the liver and excreted primarily in urine.
Sodium picosulfate is hydrolyzed by colonic bacteria to its active metabolite. Magnesium and citrate are not metabolized; they are absorbed and excreted renally.
Renal: ~80% as unchanged drug; biliary/fecal: ~20% as metabolites (glucuronide conjugates).
Sodium picosulfate is primarily excreted in feces (90-95%) as the active metabolite BHPM via biliary elimination; <5% excreted renally. Magnesium oxide is excreted renally as magnesium ions. Citric acid is metabolized to bicarbonate and excreted renally.
~40–45% bound to plasma proteins (primarily albumin).
Sodium picosulfate and its active metabolite BHPM are minimally protein bound (<5%); magnesium oxide and citric acid are not significantly protein bound.
Vd: 1.2–1.8 L/kg (total body water distribution with moderate tissue binding; higher Vd may reflect extensive extravascular distribution).
The volume of distribution of the active metabolite BHPM is not well defined; magnesium distributes mainly to extracellular fluid (0.2-0.4 L/kg).
Topical ophthalmic: minimal systemic absorption (<1% of dose enters systemic circulation).
Sodium picosulfate is a prodrug; systemic bioavailability of BHPM after oral administration is approximately 10-15% due to extensive presystemic metabolism.
No dose adjustment required; systemic absorption minimal.
Contraindicated in patients with severe renal impairment (e GFR < 30 m L/min/1.73 m²). For e GFR 30-60, use with caution and ensure adequate hydration.
No dose adjustment required; systemic absorption minimal.
No specific adjustment provided; use with caution in severe hepatic impairment (Child-Pugh C) due to potential for electrolyte disturbances.
Not recommended for pediatric use; safety and efficacy not established.
Safety and efficacy not established in pediatric patients; not recommended for use in children.
No specific dose adjustment; use with caution due to possible increased sensitivity.
No specific dose adjustment; ensure adequate hydration and monitor electrolyte levels due to increased risk of renal impairment and dehydration.
WARNING: CORNEAL TOXICITY AND IRREVERSIBLE CORNEAL DAMAGE. Prolonged use of topical anesthetics, including ALTAFLUOR BENOX, can result in delayed healing, corneal erosion, ulceration, perforation, and permanent vision loss. Use only for short-term procedures in a controlled clinical setting. Do not dispense to patients for self-administration.
Risk of acute phosphate nephropathy and renal failure, particularly in patients at increased risk (e.g., renal impairment, dehydration, medications affecting renal function).
For topical ophthalmic use only. Not for injection.,Prolonged use may cause corneal toxicity; avoid repeated instillation.,Patients should avoid touching or rubbing the eye until anesthesia wears off.,Use with caution in patients with known hypersensitivity to ester-type anesthetics or fluorescein.,May cause transient stinging, burning, or conjunctival hyperemia.,Soft contact lenses should be removed before application and may be stained by fluorescein.
Do not use in patients with gastrointestinal obstruction, perforation, or ileus.,Use caution in patients with renal impairment, electrolyte abnormalities, or those taking medications that affect electrolyte balance.,Monitor for fluid and electrolyte disturbances.,Avoid use in patients with known hypersensitivity to any component.
Known hypersensitivity to benoxinate, fluorescein, or any component of the formulation.,Prolonged use (not indicated for repeated or long-term treatment).,Use in patients with corneal abrasions or epithelial defects (may delay healing).
Gastrointestinal obstruction, ileus, or perforation,Renal failure (creatinine clearance < 30 m L/min),Ascites,Congestive heart failure (NYHA class III or IV),Known hypersensitivity to any component
No specific food interactions. Avoid alcohol as it may increase risk of dizziness or syncope during eye procedures.
Avoid solid food during bowel preparation. Consume only clear liquids (water, clear broth, apple juice, clear gelatin, black coffee or tea without milk, sports drinks). Avoid red, purple, or orange liquids that can be mistaken for blood during colonoscopy. Do not consume alcohol or dairy products.
ALTAFLUOR BENOX contains fluorescein sodium and benoxinate hydrochloride. Fluorescein is not systemically absorbed in significant amounts after topical ophthalmic administration. No teratogenic effects are expected in any trimester. Benoxinate is an ester-type local anesthetic; systemic absorption is minimal. No known teratogenic risk.
No adequate studies in pregnant women. In animal studies, sodium picosulfate showed no teratogenic effects at clinically relevant doses. Theoretical risk of electrolyte disturbances from magnesium absorption may affect fetal development; avoid in first trimester if possible. Insufficient data for second and third trimesters; use only if clearly needed.
Minimal systemic absorption of fluorescein and benoxinate after topical ophthalmic use suggests negligible excretion into breast milk. M/P ratio is not applicable. Generally considered compatible with breastfeeding.
Unknown if components excreted in human milk. Sodium picosulfate may be excreted in small amounts; magnesium and citrate are normal milk constituents. Risk to infant considered low with single doses, but caution advised with chronic use. M/P ratio not available.
No dose adjustments needed. Pharmacokinetic changes in pregnancy do not affect topical ophthalmic drug delivery. Use standard adult dose, 1-2 drops prior to procedure.
No pharmacokinetic studies in pregnancy suggest dose adjustment. Use lowest effective dose and shortest duration. Avoid chronic use due to risk of electrolyte imbalances. Single-dose bowel preparation typical; no adjustment recommended.
ALTAFLUOR BENOX (benzocaine 20% and fluorescein 0.25%) ophthalmic solution is used for corneal anesthesia and fluorescein staining. Apply 1-2 drops topically before procedures. Avoid prolonged use as benzocaine can cause corneal toxicity and delay healing. Fluorescein may stain soft contact lenses permanently; remove before use. Use with caution in patients with sulfonamide allergy (possible cross-reactivity with fluorescein). After use, patients should not rub eyes to prevent corneal abrasion.
Ensure adequate hydration to prevent electrolyte disturbances. Monitor renal function and serum electrolytes, especially in elderly or patients with renal impairment. Administer as a split-dose regimen for optimal bowel cleansing. Avoid use in patients with gastrointestinal obstruction, perforation, or severe inflammatory bowel disease.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before use and wait at least 15 minutes before reinserting.,Temporary blurred vision and stinging may occur; avoid driving until vision clears.,Do not use more often or longer than prescribed to prevent eye damage.,Tell your doctor if you have sulfa allergy or if you are pregnant or breastfeeding.
Take this medication exactly as prescribed to prepare your colon for a procedure.,Drink plenty of clear liquids before, during, and after taking this medication to prevent dehydration.,You may experience bloating, cramping, or nausea; these are common and usually resolve after the bowel movement begins.,Do not take any other laxatives or stool softeners while using this product unless directed by your doctor.,Stop taking and contact your doctor if you experience severe abdominal pain, vomiting, or signs of an allergic reaction (rash, itching, swelling).,This medication will cause frequent, watery bowel movements; stay near a bathroom.
No interactions on record
"Amphetamine increases renal tubular pH, which reduces the excretion rate of magnesium oxide, potentially leading to elevated serum magnesium levels. This interaction may result in hypermagnesemia, manifesting as hypotension, respiratory depression, or cardiac arrhythmias, particularly in patients with renal impairment."
"Mesoridazine, a phenothiazine antipsychotic, can chelate with magnesium ions in the gastrointestinal tract, forming insoluble complexes that reduce the absorption of magnesium oxide. This leads to diminished serum magnesium concentrations, potentially compromising magnesium's therapeutic effects for conditions such as hypomagnesemia or constipation. Clinically, patients may experience inadequate magnesium supplementation, risking exacerbation of electrolyte imbalances or reduced efficacy of magnesium-based therapies."
"Coadministration of magnesium oxide with rosuvastatin may decrease the serum concentration of rosuvastatin, potentially reducing its cholesterol-lowering efficacy. This interaction is thought to be due to chelation of the statin by magnesium ions in the gastrointestinal tract, impairing absorption. Clinically, this may lead to suboptimal lipid control and increased cardiovascular risk."
Common clinical questions about ALTAFLUOR BENOX vs CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE, answered by our medical review team.
ALTAFLUOR BENOX is a Ophthalmic Diagnostic Agent with Anesthetic that works by ALTAFLUOR BENOX is a combination of benoxinate, a local anesthetic that reversibly blocks sodium ion channels in nerve cell membranes, stabilizing the neuronal membrane and inhibiting the initiation and conduction of nerve impulses, and fluorescein, a fluorescent dye that stains epithelial defects in the cornea. Local anesthetic effect occurs within seconds.. CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE is a Laxative (Osmotic/Stimulant Combination) that works by Sodium picosulfate is a stimulant laxative that is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane, which stimulates colonic peristalsis by acting on the colonic mucosa and inhibiting water and electrolyte absorption. Magnesium oxide acts as an osmotic laxative by drawing water into the intestinal lumen. Citric acid reacts with magnesium oxide to form magnesium citrate, an osmotic laxative.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALTAFLUOR BENOX and CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALTAFLUOR BENOX is: 1-2 drops of 0.4% benoxinate hydrochloride ophthalmic solution instilled into the conjunctival sac prior to diagnostic procedures or surgery.. The standard adult dose of CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE is: Adult: 10 mg oral sodium picosulfate (as 10 mg powder for oral solution) plus 3.5 g magnesium oxide and 12 g citric acid, taken as a single dose the day before colonoscopy, followed by a second dose the next morning, for a total of 2 doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALTAFLUOR BENOX and CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALTAFLUOR BENOX is classified as Category C. ALTAFLUOR BENOX contains fluorescein sodium and benoxinate hydrochloride. Fluorescein is not systemically absorbed in significant amounts after topical ophthalmic administration. N. CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE is classified as Category C. No adequate studies in pregnant women. In animal studies, sodium picosulfate showed no teratogenic effects at clinically relevant doses. Theoretical risk of electrolyte disturbance. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.